Risk of carotid atherosclerosis is associated with low serum paraoxonase (PON1) activity among arsenic exposed residents in Southwestern Taiwan

Toxicology and Applied Pharmacology

Volumn 236, Issue 2, 2009, Pages 246-253

  Li, Wan Fen ^a   Sun, Chien Wen ^a   Cheng, Tain Junn ^b,c   Chang, Kuang Hsi ^a   Chen, Chien Jen ^d   Wang, Shu Li ^a,e  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d GENOMICS RESEARCH CENTER   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Arsenic; Atherosclerosis; Cardiovascular disease; Paraoxonase; Polymorphism

Indexed keywords

ARSENIC; ARYLDIALKYLPHOSPHATASE 1; ARYLDIALKYLPHOSPHATASE 2;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CAROTID ATHEROSCLEROSIS; CHINESE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA POLYMORPHISM; ENDEMIC DISEASE; ENZYME ACTIVITY; FEMALE; GENE CLUSTER; GENE FREQUENCY; GENETIC RISK; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; RISK ASSESSMENT; SURVIVAL; TAIWAN;

ADULT; AGED; AGED, 80 AND OVER; ARSENIC; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; CAROTID ARTERY DISEASES; CASE-CONTROL STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; RISK FACTORS;

EID: 62749203408     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2009.01.019     Document Type: Article

References (43)

1. Barchowsky A., Klei L.R., Dudek E.J., Swartz H.M., and James P.E. Stimulation of reactive oxygen, but not reactive nitrogen species, in vascular endothelial cells exposed to low levels of arsenite. Free Radic. Biol. Med. 27 (1999) 1405-1412
2. Benichou J. A review of adjusted estimators of attributable risk. Stat. Methods Med. Res. 10 (2001) 195-216
3. Bhattacharyya T., Nicholls S.J., Topol E.J., Zhang R., Yang X., Schmitt D., Fu X., Shao M., Brennan D.M., Ellis S.G., Brennan M.L., Allayee H., Lusis A.J., and Hazen S.L. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 299 (2008) 1265-1276
4. Brophy V.H., Hastings M.D., Clendenning J.B., Richter R.J., Jarvik G.P., and Furlong C.E. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 11 (2001) 77-84
5. Bruzzi P., Green S.B., Byar D.P., Brinton L.A., and Schairer C. Estimating the population attributable risk for multiple risk factors using case-control data. Am. J. Epidemiol. 122 (1985) 904-914
6. Chen C.J., Chiou H.Y., Chiang M.H., Lin L.J., and Tai T.Y. Dose-response relationship between ischemic heart disease mortality and long-term arsenic exposure. Arterioscler. Thromb. Vasc. Biol. 16 (1996) 504-510
7. Chen C.J., Hsueh Y.M., Lai M.S., Shyu M.P., Chen S.Y., Wu M.M., Kuo T.L., and Tai T.Y. Increased prevalence of hypertension and long-term arsenic exposure. Hypertension 25 (1995) 53-60
8. Chen Q., Reis S.E., Kammerer C.M., McNamara D.M., Holubkov R., Sharaf B.L., Sopko G., Pauly D.F., Merz C.N., and Kamboh M.I. Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. Am. J. Hum. Genet. 72 (2003) 13-22
9. Chen Y.C., Lin-Shiau S.Y., and Lin J.K. Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. J. Cell Physiol. 177 (1998) 324-333
10. Chiou H.Y., Huang W.I., Su C.L., Chang S.F., Hsu Y.H., and Chen C.J. Dose-response relationship between prevalence of cerebrovascular disease and ingested inorganic arsenic. Stroke 28 (1997) 1717-1723
11. Christiansen L., Bathum L., Frederiksen H., and Christensen K. Paraoxonase 1 polymorphisms and survival. Eur. J. Hum. Genet. 12 (2004) 843-847
12. Cole T.B., Li W.F., Richter R.J., Furlong C.E., and Costa L.G. Inhibition of paraoxonase (PON1) by heavy metals. Toxicol. Sci. 66 (2002) 312
13. de Groot E., Hovingh G.K., Wiegman A., Duriez P., Smit A.J., Fruchart J.C., and Kastelein J.J. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation 109 (2004) III33-III38
14. Hegele R.A., Connelly P.W., Scherer S.W., Hanley A.J., Harris S.B., Tsui L.C., and Zinman B. Paraoxonase-2 gene (PON2) G148 variant associated with elevated fasting plasma glucose in noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 82 (1997) 3373-3377
15. Hegele R.A., Harris S.B., Connelly P.W., Hanley A.J., Tsui L.C., Zinman B., and Scherer S.W. Genetic variation in paraoxonase-2 is associated with variation in plasma lipoproteins in Canadian Oji-Cree. Clin. Genet. 54 (1998) 394-399
16. Humbert R., Adler D.A., Disteche C.M., Hassett C., Omiecinski C.J., and Furlong C.E. The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Genet. 3 (1993) 73-76
17. Jarvik G.P., Rozek L.S., Brophy V.H., Hatsukami T.S., Richter R.J., Schellenberg G.D., and Furlong C.E. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 2441-2447
18. Kuo T.L. Arsenic content of artesian well water in endemic area of chronic arsenic poisoning. Rep. Inst. Pathol. Coll. Med. Natl. Taiwan Univ. 20 (1964) 7-13
19. Lee P.C., Ho I.C., and Lee T.C. Oxidative stress mediates sodium arsenite-induced expression of heme oxygenase-1, monocyte chemoattractant protein-1, and interleukin-6 in vascular smooth muscle cells. Toxicol. Sci. 85 (2005) 541-550
20. Leus F.R., Zwart M., Kastelein J.J., and Voorbij H.A. PON2 gene variants are associated with clinical manifestations of cardiovascular disease in familial hypercholesterolemia patients. Atherosclerosis 154 (2001) 641-649
21. Li W.F., Pan M.H., Chung M.C., Ho C.K., and Chuang H.Y. Lead exposure is associated with decreased serum paraoxonase 1 (PON1) activity and genotypes. Environ. Health Perspect. 114 (2006) 1233-1236
22. Lo M.C., Hsen Y.C., and Lin B.K. Arsenic Content of Underground Water in Taiwan: Second Report (1977), Taiwan Provincial Institute of Environmental Sanitation, Taichung, Taiwan 1-17
23. Lorenz M.W., Markus H.S., Bots M.L., Rosvall M., and Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 115 (2007) 459-467
24. Mackness B., Davies G.K., Turkie W., Lee E., Roberts D.H., Hill E., Roberts C., Durrington P.N., and Mackness M.I. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype?. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1451-1457
25. Mackness B., Durrington P., McElduff P., Yarnell J., Azam N., Watt M., and Mackness M. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 107 (2003) 2775-2779
26. Mochizuki H., Scherer S.W., Xi T., Nickle D.C., Majer M., Huizenga J.J., Tsui L.C., and Prochazka M. Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene 213 (1998) 149-157
27. Navas-Acien A., Sharrett A.R., Silbergeld E.K., Schwartz B.S., Nachman K.E., Burke T.A., and Guallar E. Arsenic exposure and cardiovascular disease: a systematic review of the epidemiologic evidence. Am. J. Epidemiol. 162 (2005) 1037-1049
28. Ng C.J., Bourquard N., Grijalva V., Hama S., Shih D.M., Navab M., Fogelman A.M., Lusis A.J., Young S., and Reddy S.T. Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins: anti-atherogenic role for paraoxonase-2. J. Biol. Chem. 281 (2006) 29491-29500
29. Pan J.P., Lai S.T., Chiang S.C., Chou S.C., and Chiang A.N. The risk of coronary artery disease in population of Taiwan is associated with Cys-Ser 311 polymorphism of human paraoxonase (PON)-2 gene. Zhonghua Yi Xue Za Zhi (Taipei) 65 (2002) 415-421
30. Pi J., Yamauchi H., Kumagai Y., Sun G., Yoshida T., Aikawa H., Hopenhayn-Rich C., and Shimojo N. Evidence for induction of oxidative stress caused by chronic exposure of Chinese residents to arsenic contained in drinking water. Environ. Health Perspect. 110 (2002) 331-336
31. Shih D.M., Gu L., Xia Y.R., Navab M., Li W.F., Hama S., Castellani L.W., Furlong C.E., Costa L.G., Fogelman A.M., and Lusis A.J. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394 (1998) 284-287
32. States J.C., Srivastava S., Chen Y., and Barchowsky A. Arsenic and cardiovascular disease. Toxicol. Sci. 107 (2009) 312-323
33. Su S.Y., Chen J.H., Huang J.F., Wang X.L., Zhao J.G., Shen Y., Qiang B.Q., and Gu D.F. Paraoxonase gene cluster variations associated with coronary heart disease in Chinese Han women. Chin. Med. J. 118 (2005) 1167-1174
34. Tseng C.H., Chong C.K., Chen C.J., and Tai T.Y. Dose-response relationship between peripheral vascular disease and ingested inorganic arsenic among residents in blackfoot disease endemic villages in Taiwan. Atherosclerosis 120 (1996) 125-133
35. Tseng C.H., Huang Y.K., Huang Y.L., Chung C.J., Yang M.H., Chen C.J., and Hsueh Y.M. Arsenic exposure, urinary arsenic speciation, and peripheral vascular disease in blackfoot disease-hyperendemic villages in Taiwan. Toxicol. Appl. Pharmacol. 206 (2005) 299-308
36. Tward A., Xia Y.R., Wang X.P., Shi Y.S., Park C., Castellani L.W., Lusis A.J., and Shih D.M. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 106 (2002) 484-490
37. Wang C.H., Jeng J.S., Yip P.K., Chen C.L., Hsu L.I., Hsueh Y.M., Chiou H.Y., Wu M.M., and Chen C.J. Biological gradient between long-term arsenic exposure and carotid atherosclerosis. Circulation 105 (2002) 1804-1809
38. Wang T.S., Kuo C.F., Jan K.Y., and Huang H. Arsenite induces apoptosis in Chinese hamster ovary cells by generation of reactive oxygen species. J. Cell. Physiol. 169 (1996) 256-268
39. Wang X., Fan Z., Huang J., Su S., Yu Q., Zhao J., Hui R., Yao Z., Shen Y., Qiang B., and Gu D. Extensive association analysis between polymorphisms of PON gene cluster with coronary heart disease in Chinese Han population. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 328-334
40. Wang Y.H., Wu M.M., Hong C.T., Lien L.M., Hsieh Y.C., Tseng H.P., Chang S.F., Su C.L., Chiou H.Y., and Chen C.J. Effects of arsenic exposure and genetic polymorphisms of p53, glutathione S-transferase M1, T1, and P1 on the risk of carotid atherosclerosis in Taiwan. Atherosclerosis 192 (2007) 305-312
41. Wheeler J.G., Keavney B.D., Watkins H., Collins R., and Danesh J. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 363 (2004) 689-695
42. Wu M.M., Chiou H.Y., Ho I.C., Chen C.J., and Lee T.C. Gene expression of inflammatory molecules in circulating lymphocytes from arsenic-exposed human subjects. Environ. Health Perspect. 111 (2003) 1429-1438
43. Wu M.M., Chiou H.Y., Wang T.W., Hsueh Y.M., Wang I.H., Chen C.J., and Lee T.C. Association of blood arsenic levels with increased reactive oxidants and decreased antioxidant capacity in a human population of northeastern Taiwan. Environ. Health Perspect. 109 (2001) 1011-1017